These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 34478159)
1. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159 [TBL] [Abstract][Full Text] [Related]
2. Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma. Zhao L; Wang Y; Tian T; Rao X; Dong W; Zhang J; Yang Y; Tao Q; Peng F; Shen C; Wang S; Liu H; Zeng X; Zhou W Hepatol Int; 2022 Dec; 16(6):1339-1352. PubMed ID: 36123506 [TBL] [Abstract][Full Text] [Related]
3. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
4. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis. Schäffer AA; Dominguez DA; Chapman LM; Gertz EM; Budhu A; Forgues M; Chaisaingmongkol J; Rabibhadana S; Pupacdi B; Wu X; Bayarsaikhan E; Harris CC; Ruchirawat M; Ruppin E; Wang XW BMC Genomics; 2021 Nov; 22(1):814. PubMed ID: 34763675 [TBL] [Abstract][Full Text] [Related]
5. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification. Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585 [TBL] [Abstract][Full Text] [Related]
6. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Sasaki M; Sato Y; Nakanuma Y Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197 [TBL] [Abstract][Full Text] [Related]
7. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Sasaki M; Sato Y; Nakanuma Y Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959 [TBL] [Abstract][Full Text] [Related]
9. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330 [TBL] [Abstract][Full Text] [Related]
10. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764 [TBL] [Abstract][Full Text] [Related]
11. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma. Sasaki M; Sato Y; Nakanuma Y Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289 [TBL] [Abstract][Full Text] [Related]
13. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas. Sasaki M; Sato Y; Nakanuma Y Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357 [TBL] [Abstract][Full Text] [Related]
14. MRI for Hepatitis B-Associated Intrahepatic Cholangiocarcinoma: A Multicenter Comparative Study. Sheng R; Wang H; Zhang Y; Sun W; Jin K; Dai Y; Zhang W; Zeng M; Zhou J J Magn Reson Imaging; 2024 Mar; 59(3):1093-1104. PubMed ID: 37309823 [TBL] [Abstract][Full Text] [Related]
15. MYC determines lineage commitment in KRAS-driven primary liver cancer development. D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma. Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761 [TBL] [Abstract][Full Text] [Related]
18. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features. Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316 [TBL] [Abstract][Full Text] [Related]
19. Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas. Kikuchi AT; Umetsu S; Joseph N; Kakar S Am J Surg Pathol; 2023 Nov; 47(11):1207-1218. PubMed ID: 37661782 [TBL] [Abstract][Full Text] [Related]
20. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Sia D; Villanueva A; Friedman SL; Llovet JM Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]